No Data
No Data
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Express News | Skye Bioscience Shares Are Trading Higher After the Company Announced That It Started Screening Patients for a Phase 2 Clinical Trial of Nimacimab
Express News | Skye Bioscience Has Started Screening Patients For Phase 2 Trial (Cbeyond) Of Nimacimab, A Negative Allosteric Modulating Antibody As Weight Loss Therapeutic In Obese Patients, Interim Data Is Expected In Q2 Of 2025 And Final Data In Q4 Of 2025
Express News | Skye Bioscience Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated CB1 Inhibitor, Nimacimab, in Patients With Obesity
Skye Bioscience GAAP EPS of -$0.20 Beats by $0.01
No Data